+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Car T Therapies"

From
Cancer Immunotherapy: Technologies and Global Markets - Product Thumbnail Image

Cancer Immunotherapy: Technologies and Global Markets

  • Report
  • April 2025
  • 203 Pages
  • Global
From
From
Oncology Pharmaceuticals Market - Product Thumbnail Image

Oncology Pharmaceuticals Market

  • Report
  • October 2024
  • 181 Pages
  • Global
From
From
From
From
From
From
From
From
From
Checkpoint Inhibitors Market Report 2025 - Product Thumbnail Image

Checkpoint Inhibitors Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Drugs for Immunotherapy Market Report 2025 - Product Thumbnail Image

Drugs for Immunotherapy Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Loading Indicator

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer. Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer. Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more